Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Am I mad or is it the meds?

It’s 00:50 and once again I can’t sleep. My insomnia has kept me up for the best part of three days in a row now, my mind is tired, my body is exhausted and yet I still can’t sleep.

Published
07 June 2013
From
UK Positive Lad (blog)
Bone loss and fracture risk are 'modest' among HIV+ people, linked to tenofovir, smoking, and HCV

Continued bone loss among HIV positive men with osteopenia was modest overall, but about 25% of those taking tenofovir (Viread, also in 4 antiretroviral coformulations) experienced significant loss, according to a recent study. A related meta-analysis found that HIV infection is associated with a modest likelihood of new fractures, with smoking and hepatitis C virus (HCV) coinfection further increasing the risk.

Published
07 June 2013
From
HIVandHepatitis.com
NIH scientists discover how HIV kills immune cells

Untreated HIV infection destroys a person's immune system by killing infection-fighting cells, but precisely when and how HIV wreaks this destruction has been a mystery until now. New research by scientists at NIAID reveals how HIV triggers a signal telling an infected immune cell to die. This finding has implications for preserving the immune systems of HIV-infected individuals.

Published
07 June 2013
From
Eurekalert Inf Dis
People doing well on HIV therapy have a mortality risk identical to that of HIV-negative peers

HIV-positive people taking antiretroviral therapy who have an undetectable viral load and a CD4 cell count above 500 cells/mm3 have a mortality risk comparable to that seen

Published
05 June 2013
By
Michael Carter
Liquid Injectable Silicone Effective, Safe for Treating HIV Patients with Facial Lipoatrophy

Research in British Columbia, Canada, indicates that liquid injectable silicone administered properly has potential as a safe, effective, natural feeling treatment for patients with HIV-associated facial lipoatrophy (FLA). The researchers tested liquid injectable silicone because temporary filler treatments were not permanent and could result in high costs.

Published
04 June 2013
From
Healio
Is Long-Term Treatment Better with Raltegravir Than with Efavirenz?

Five-year follow-up of a blinded, prospective clinical trial demonstrated that raltegravir has a better side-effect profile, which ultimately leads to better outcomes.

Published
04 June 2013
From
Journal Watch
Nevirapine dose escalation for children may risk treatment failure

Full-dose nevirapine should be considered for HIV-positive children under two years of age in Africa, to simplify ART initiation and reduce the risk of suboptimal dosing, researchers reporting

Published
03 June 2013
By
Carole Leach-Lemens
HIV cure: the long road ahead

Scientists from around the world met to review the future of HIV scientific research at the Institut Pasteur in Paris, last week – 30 years after the

Published
31 May 2013
By
Keith Alcorn
European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg), a single tablet regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.

Published
28 May 2013
From
Gilead press release
HIV cure: scientific reality or media hype?

Dr John Frater of the University of Oxford comments on recent HIV cure research.

Published
24 May 2013
From
The Conversation

Filter by country